Oct 9, 2026 3-5pm ET

Friday on The Robert Scott Bell Show:





Hour 1

NIH Will Run Vaccine Injury Research and Treatment Center, Pay Doctors to Report Vaccine Injuries The U.S. Department of Health and Human Services announced on October 8, 2026, that the National Institutes of Health will operate a new clinic dedicated to studying health problems reported after vaccination and developing potential treatments for affected patients. The initiative also includes plans to modernize the Vaccine Adverse Event Reporting System (VAERS), reimburse physicians for reporting suspected vaccine injuries, introduce a new medical billing code for such reports and require electronic health records to capture vaccine-related adverse events. Health Secretary Robert F. Kennedy Jr. attended a closed-door ribbon-cutting ceremony on October 5 at the NIH campus in Bethesda, Maryland, alongside NIH Director Jay Bhattacharya, Acting FDA Commissioner Kyle Diamantas, CDC Director Erica Schwartz, CMS Administrator Mehmet Oz and families who attribute serious injuries to vaccines. Children’s Health Defense representative Polly Tommey described the event as an important acknowledgment of families who believe federal health authorities previously dismissed their experiences. Parents Krystle Cordingley and Jordan Grim expressed cautious optimism, while emphasizing that meaningful progress must include treatment and sustained research rather than symbolic recognition. The program follows recommendations in the September 2025 Make America Healthy Again Commission strategy report calling for improved vaccine safety surveillance and a dedicated NIH research initiative. The clinic will combine specialized patient evaluations with scientific investigations into possible biological mechanisms underlying adverse reactions. Research may examine persistent fatigue, neurological symptoms and inflammation associated with what some investigators describe as post-vaccination syndrome, which can overlap symptomatically with long COVID. Yale cardiologist Harlan Krumholz and Johns Hopkins vaccine safety researcher Daniel Salmon welcomed additional scientific investigation. Planned VAERS improvements include mobile reporting capabilities, better analytical tools and QR codes on vaccine information statements. The article also raises concerns about underreporting, although reports of adverse events do not independently establish that vaccination caused a particular medical condition. Funding arrangements remain unresolved, with some resources potentially coming from existing long COVID research allocations. Families also cited previous federal investigations that failed to produce lasting results. The initiative represents an expanded federal commitment to investigating suspected vaccine injuries, but its effectiveness will depend on transparent research, reliable causal assessment, appropriate clinical care and sustained financial support.


Vaccine Injury: A Glimpse of the Scale Pediatrician Dr. Elizabeth Mumper, drawing on 46 years of clinical experience, presented concerns about vaccine safety, childhood chronic illness and gaps in medical research during a special National Institutes of Health event at which families reporting vaccine injuries shared their experiences. Mumper, who previously served as medical director of the Autism Research Institute and treated or consulted on more than 600 children with autism, described how a severe reaction in one of her patients in 1999 changed her professional approach. She subsequently established a practice focused on children with complex medical conditions, investigating gastrointestinal dysfunction, immune abnormalities, mitochondrial problems, methylation disturbances and cerebral folate deficiency. According to Mumper, treating these underlying conditions sometimes produced substantial improvements in developmental and behavioral symptoms, although these clinical observations do not independently establish the effectiveness of particular treatments or a causal relationship between vaccination and autism. She argues that childhood vaccine safety research should examine individual biological vulnerabilities rather than treating all children as having identical risk profiles. Mumper recounts professional resistance after questioning vaccination schedules, including the nonrenewal of an academic appointment following a 2005 presentation. She also describes a 17-year research project involving her pediatric practice, reporting an autism prevalence of approximately one in 297 after seven years, compared with national estimates exceeding one in 50. She further claims that children receiving more vaccines experienced higher rates of certain chronic conditions, including developmental delays, asthma and ear infections. Her comparisons included families choosing religious or philosophical vaccine exemptions, representing approximately 30 percent of her practice. Such observational comparisons require careful consideration of selection bias, confounding factors and differences in healthcare utilization before causal conclusions can be drawn. Mumper additionally references an unpublished Henry Ford Health birth-cohort analysis involving approximately 18,000 children, reporting chronic illness among 57 percent of vaccinated children compared with 17 percent of unvaccinated children after ten years. Because the analysis was unpublished, its methods and conclusions have not undergone the same public scientific scrutiny as peer-reviewed research. She identifies genetic variants involving CCL2, NLRP3 and CARD8 as potential areas for investigating susceptibility to adverse reactions. Her three principal recommendations are to discontinue mRNA vaccination for children and adolescents, fund NIH research focused on treatment strategies for patients reporting vaccine injuries, and investigate genetic, metabolic and inflammatory characteristics that might help identify susceptible children. The presentation ultimately advocates individualized risk assessment and expanded research into suspected vaccine-related harm, while many of its broader causal claims remain contested and require stronger independent evidence.


New Study Reveals Children’s Alarming Pesticide Burden A new biomonitoring study examining pesticide exposure among infants and young children found an average of 31 pesticide-related compounds per child, raising concerns about cumulative chemical exposure during critical periods of neurological, immune and reproductive development. Researchers analyzed 438 urine samples collected from 187 children ranging in age from just 10 days to seven years. Across the samples, investigators reported 215 pesticide and pesticide-metabolite identifications corresponding to 160 distinct active substances, with individual children showing between 21 and 50 compounds. Sixteen substances were detected in more than 60 percent of participants, and approximately 40 percent of the identified compounds were metabolites produced as pesticides break down in the body. The remaining findings included insecticides, herbicides, fungicides, repellents and other substances. The study measured exposure rather than clinical outcomes, meaning it did not establish that the detected chemicals caused illness among participating children. Nevertheless, the Alliance for Natural Health USA argues that the findings expose limitations in federal pesticide regulation, particularly the tendency to evaluate individual active ingredients rather than the combinations of chemicals encountered in everyday environments. The organization references a 2026 meta-analysis involving 46 studies and nearly 26,000 participants that associated prenatal organophosphate exposure with poorer cognitive and neurodevelopmental outcomes. Additional research involving more than 1,000 mother-child pairs associated prenatal exposure to mixtures of organophosphate, pyrethroid and neonicotinoid insecticides with lower mental-development scores among two-year-old boys. Other studies have reported associations between pesticide exposure and childhood leukemia, asthma, reproductive abnormalities and neurological conditions, although the strength and causal interpretation of these associations vary. The article also raises concerns about so-called inert pesticide ingredients, including solvents, surfactants and preservatives, which may influence the toxicity of commercial formulations. It cites laboratory research suggesting that some complete pesticide products were substantially more toxic to human cells than their active ingredients alone, although laboratory toxicity cannot be directly equated with real-world human exposure risk. ANH-USA advocates two legislative responses: the Paraquat Prevention Act, H.R. 9357, introduced by Representatives Anna Paulina Luna and Chellie Pingree, which would eliminate registered paraquat uses and prohibit future sales, and the Opportunities in Organic Act, S. 3717 and H.R. 7318, which would expand financial and technical assistance for farmers transitioning toward organic agriculture. Recommended household precautions include washing produce, reducing unnecessary pesticide applications and choosing organic foods when feasible. The broader policy argument is that protecting children requires evaluating chemical mixtures, improving regulatory transparency and reducing hazardous exposures at their sources rather than relying exclusively on individual consumer choices.


When Did Obesity Become a Drug Deficiency? The rapid growth of obesity in the United States reflects profound changes in food systems, physical activity, sleep, environmental exposures and daily living conditions, yet modern medicine increasingly concentrates on pharmaceutical treatments rather than the societal factors contributing to the epidemic. Physician Joseph Varon notes that approximately 13 percent of American adults were classified as obese during the early 1960s, compared with 40.3 percent by August 2023, while another 31.7 percent were overweight and nearly one in ten had severe obesity. He argues that genetic changes cannot explain such a dramatic population-wide increase over a relatively short historical period. Instead, he identifies widespread availability of ultra-processed foods, larger portions, sedentary employment, reduced physical activity, inadequate sleep, stress and potentially metabolism-disrupting environmental chemicals as interacting contributors. A controlled National Institutes of Health study demonstrated that participants consuming ultra-processed diets ate approximately 500 additional calories daily and gained weight compared with participants consuming minimally processed foods, despite diets being matched for several nutritional characteristics. Varon acknowledges that newer obesity medications, particularly semaglutide and tirzepatide, represent substantial therapeutic advances. In the STEP 1 clinical trial, semaglutide produced average weight loss of 14.9 percent over 68 weeks, compared with 2.4 percent among placebo recipients. In the SURMOUNT-1 trial, tirzepatide produced average reductions of 15 to 20.9 percent depending on dosage, compared with 3.1 percent for placebo. Beyond weight reduction, the SELECT trial found major cardiovascular events in 6.5 percent of semaglutide recipients compared with 8 percent of placebo recipients, while tirzepatide has demonstrated meaningful improvements in obesity-related obstructive sleep apnea. These findings support legitimate medical applications rather than dismissing the medications as cosmetic interventions. However, Varon emphasizes that discontinuation frequently results in substantial weight regain. Participants stopping semaglutide regained approximately two-thirds of their previous weight loss within one year, while tirzepatide withdrawal produced similar difficulties maintaining results. This raises questions about long-term treatment dependence, financial costs, medication accessibility, adverse effects and preservation of lean muscle mass. Although the American Diabetes Association and World Health Organization recognize roles for sustained obesity pharmacotherapy, Varon argues that medication should complement, rather than replace, efforts to improve food quality, community design, physical activity opportunities and environmental conditions. He also distinguishes respectful treatment of people with obesity from minimizing the medical consequences of excessive body fat. His central argument is that successful pharmaceutical management does not explain why obesity became so prevalent, and an exclusive focus on prescriptions risks leaving the underlying public health problem unresolved.


Welcome back to another “Homeopathic Hits” episode on The Robert Scott Bell Show!
Today’s Homeopathic Hit is Oleum santali, Oil of Sandalwood.
Boericke highlights this remedy for the urinary and sexual spheres, especially in gonorrhoea, gleet, chronic cystitis, burning and smarting urination, and thick muco-purulent discharge. It is also noted as a stimulating, disinfectant expectorant for hacking cough with little sputum.

Download the  Information Sheet


Hour 2

 

Ottawa to indefinitely extend MAID exclusion for people solely suffering from mental illness Canada’s federal government announced on October 7, 2026, that it will introduce legislation to indefinitely prohibit medical assistance in dying (MAID) when a person’s sole underlying medical condition is mental illness, reversing a previously scheduled expansion of eligibility set for March 17, 2027. Justice Minister Sean Fraser said the decision follows recommendations from a special parliamentary committee released in June and reflects two principal concerns: inadequate access to mental health services in some communities and the absence of medical consensus about when psychiatric conditions can be considered incurable. Canada legalized MAID in 2016, initially limiting eligibility to people whose natural deaths were reasonably foreseeable. Following a 2019 Quebec court decision, Parliament passed Bill C-7 in March 2021, removing that requirement and extending eligibility to certain individuals with serious, incurable conditions who were not approaching death. However, eligibility based solely on mental illness was repeatedly postponed, first until 2023, then 2024, and finally March 2027. Fraser’s proposed legislation would eliminate that scheduled expansion rather than establish another temporary delay. The government also intends to introduce provisions permitting advance requests for assisted dying by individuals diagnosed with serious, incurable illnesses that may eventually destroy their ability to provide informed consent. Such requests could affect patients with neurodegenerative conditions, including Alzheimer’s disease, although eligibility requirements and implementation details remain subject to parliamentary consideration. Fraser announced the government’s plans shortly before a House of Commons vote on Conservative MP Tamara Jansen’s private member’s Bill C-218, which also sought to prevent MAID eligibility based solely on mental illness. Fraser argued that the Conservative proposal used terminology that could inadvertently affect people with neurological diseases and failed to address advance consent. Jansen accused the government of political maneuvering and criticized its decision to oppose her bill before introducing its own legislation. Bill C-218 was defeated by 187 votes to 141, with Conservatives, New Democrats, Green Party MP Elizabeth May and two Liberal MPs supporting it. Most Liberals and Bloc Québécois MPs voted against the proposal. The government’s announcement does not change existing eligibility for people with qualifying physical medical conditions, including some individuals who also experience mental illness. The proposed changes remain subject to legislation, and the debate continues to balance personal autonomy, protection of vulnerable patients, access to psychiatric care and the difficulty of determining whether mental illness is truly irremediable.


Pediatricians renew their call for a ban on raw milk The American Academy of Pediatrics has renewed its recommendation for a ban on the sale and distribution of unpasteurized milk and dairy products, warning that raw dairy poses preventable infectious disease risks, particularly to children, pregnant women and people with weakened immune systems. The updated policy statement, published in the medical journal Pediatrics and reported by The Washington Post on October 5, 2026, argues that claims promoting raw milk as nutritionally superior or capable of improving allergies and immune function lack convincing scientific support. Dr. Adam Ratner, a pediatric infectious disease specialist and lead author of the statement, emphasized that unpasteurized milk is not demonstrably healthier than pasteurized milk and presents greater risks of foodborne illness. Pasteurization uses controlled heating to reduce potentially dangerous microorganisms while retaining the milk’s principal nutritional components. Without that process, dairy products can carry pathogens including Escherichia coli, Listeria monocytogenes and Salmonella, which can cause gastrointestinal illness, bloodstream infections and other serious complications. Young children are particularly vulnerable because certain infections can progress to dehydration, kidney damage or life-threatening systemic disease. The academy also cautions that risks are not limited to drinking raw milk directly. Unpasteurized yogurt, ice cream and cheeses, including some aged hard cheeses, can transmit pathogens if contamination occurs. The policy statement additionally addresses highly pathogenic avian influenza A(H5N1), which was detected in raw milk samples during the 2024 outbreak affecting American dairy cattle. Ratner described the detection as concerning, although the article notes that no confirmed human infections had been attributed to transmission through consuming dairy products. Detection of viral material in milk does not independently establish that drinking it causes infection, but it adds another consideration to dairy safety assessments. Raw milk supporters frequently emphasize traditional food production, consumer choice and proposed benefits associated with naturally occurring microorganisms or enzymes. The pediatricians maintain that such proposed advantages have not been established sufficiently to outweigh documented bacterial risks. Their renewed recommendation favors restrictions on commercial distribution as a preventive public health measure, reflecting a continuing disagreement between medical organizations advocating pasteurization and consumers who favor access to unprocessed dairy products.


Can GLP-1 drugs help stop compulsive shopping, gambling and other ways people throw away their money? Researchers at the University of Pennsylvania’s Wharton School are launching a study to investigate whether GLP-1 medications, widely prescribed for diabetes and obesity, can also influence financial decision-making by reducing impulsive spending, gambling and other reward-seeking behaviors. Neuroscientist and Wharton professor Michael Platt believes these medications may affect brain circuits involved in evaluating rewards and resisting immediate gratification, potentially extending their effects beyond appetite regulation. GLP-1 medications such as semaglutide and tirzepatide influence metabolic signaling and have attracted growing scientific interest because some patients report changes in cravings and other compulsive behaviors while taking them. However, whether those observations translate into measurable improvements in financial judgment remains an open research question. The Wharton investigation, funded by digital health company Noom, builds partly on earlier research involving Noom CEO Geoff Cook. Researchers plan to recruit approximately 180 participants for testing at the university’s MindCORE research laboratory between mid-October 2026 and March 2027. Participants will provide demographic and mental health information, disclose whether they use GLP-1 medications and complete cognitive assessments before undergoing functional magnetic resonance imaging. The researchers will monitor activity in brain regions associated with reward processing, valuation and decision-making while participants complete four tasks, two involving food and two involving financial choices. One exercise will present 14 images depicting products, services and spending opportunities, including lottery jackpots, allowing investigators to measure spontaneous responses without requiring an immediate decision. Recognizable brand logos will be excluded to reduce the influence of brand familiarity. Another exercise will ask participants to choose between immediate and delayed financial rewards, such as receiving $20 immediately or $50 after two months. Participants will subsequently receive the outcome of one selected decision, creating real financial consequences rather than relying entirely on hypothetical preferences. Platt suggests that changes in reward sensitivity could encourage saving and discourage risky purchases, although reduced reward-seeking might also have implications for activities requiring risk tolerance, including certain investment decisions. CBS cites a 2026 Northwestern Mutual study reporting that 73 percent of Americans had participated in or considered speculative financial activities such as sports betting or cryptocurrency investment. The Wharton project is designed to investigate potential relationships between GLP-1 use and neural responses, not to establish in advance that these medications treat gambling disorder or compulsive shopping. The research could eventually clarify whether drugs developed for metabolic conditions influence broader behavioral patterns, but clinical effectiveness, long-term consequences and appropriate medical applications remain unproven..


Baby sleep supplement recalled after FDA finds alcohol in bottles Pacific Health Sciences voluntarily recalled one production lot of Babies’ Magic Tea brand Baby Sleep Gripe Water after laboratory testing by the U.S. Food and Drug Administration identified three undeclared alcohols in a dietary supplement marketed for infants. The company announced the recall on October 6, 2026, and the FDA published its notice the following day. Testing identified approximately 8.3 percent ethanol, 0.35 percent methanol and 0.48 percent isopropanol in the affected product, none of which appeared on its ingredient label. Ethanol is the type of alcohol found in alcoholic beverages, while methanol and isopropanol are different alcohol compounds with distinct toxicological properties. Their presence in an infant product raises particular safety concerns because young children have substantially lower body weights and different capacities to tolerate certain chemical exposures. The FDA cautioned that the potential health risk depends on the quantity consumed, the child’s age and body weight. The recall applies specifically to lot number 25122bw, with a best-before date of December 2028. The affected product was sold in four-fluid-ounce amber bottles packaged inside blue cardboard boxes and accompanied by an oral dosing syringe. The lot number appears on the bottom of the box and on a side panel of the bottle. Pacific Health Sciences distributed the affected lot to Secrets of Tea for subsequent sale through online retailers, including the company’s website and Amazon. The recall announcement did not identify additional affected production lots or establish that every bottle of the product contained the same concentrations. As of the October 6 announcement, the company reported receiving no adverse-event complaints associated with the recalled lot, although the absence of reported injuries does not eliminate the potential hazard. Parents and caregivers are instructed to stop administering the affected product immediately and either discard it or return it to the place of purchase for a refund. Anyone experiencing symptoms after using the product should seek medical attention. Consumers may contact Pacific Health Sciences at 310-457-1775 or report suspected adverse reactions through the FDA’s MedWatch program. The recall is being conducted with the agency’s knowledge, and the notice does not establish how the alcohols entered the product or whether contamination occurred during manufacturing, formulation or another stage of distribution. The incident highlights the importance of accurate ingredient labeling, manufacturing quality controls and independent product testing, particularly for dietary supplements intended for infants.



Remember Friends, The Power to Heal is Yours!



What would you like to hear from The Robert Scott Bell Show? Call us at 1-866-939-BELL (2355) and let your voice be heard!

Previous episodes of the Robert Scott Bell Show: SoundCloud

Learn the best ways to keep your family fed when the trucks have stopped, the stores shut down, and no food is available. Go to http://RSBFood.com